A method to identify new molecular markers for assessing
minimal residual disease in acute leukemia patients

J 2013

A method to identify new molecular markers for assessing minimal residual disease in acute leukemia patients

JANCUSKOVA, T; R PLACHY; Jiří ŠTIKA; L ZEMANKOVA; DW HARDEKOPF et al.

Základní údaje

Originální název

A method to identify new molecular markers for assessing minimal residual disease in acute leukemia patients

Autoři

JANCUSKOVA, T; R PLACHY; Jiří ŠTIKA ; L ZEMANKOVA; DW HARDEKOPF; T LIEHR; N KOSYAKOVA; R CMEJLA; L ZEJSKOVA; T KOZAK; P ZAK; A ZAVRELOVA; P HAVLIKOVA; M KARAS; A JUNGE; C RAMEL a S PEKOVA

Vydání

Leukemia Research, OXFORD, PERGAMON-ELSEVIER SCIENCE LTD, 2013, 0145-2126

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.692

Označené pro přenos do RIV

DOI

https://doi.org/10.1016/j.leukres.2013.06.009

UT WoS

000324099100031

Klíčová slova anglicky

Acute leukemia; Minimal residual disease; Cytogenetics; Chromosome microdissection; Next-generation sequencing; Personalized medicine

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 23. 8. 2018 14:25, Mgr. Jiří Štika, Ph.D.

Anotace

V originále

Acute leukemias (AL) comprise a heterogeneous group of hematologic malignancies, and individual patient responses to treatment can be difficult to predict. Monitoring of minimal residual disease (MRD) is thus very important and holds great potential for improving treatment strategies. Common MRD targets include recurrent cytogenetic abnormalities and mutations in important hematological genes; unfortunately well-characterized targets are lacking in many AL patients. Here we demonstrate a technical approach for the identification and mapping of novel clone-specific chromosomal abnormalities down to the nucleotide level. We used molecular cytogenetics, chromosome microdissection, amplification of the microdissected material, and next-generation sequencing to develop PCR-based MRD assays based on unique breakpoint sequences. (C) 2013 Elsevier Ltd. All rights reserved.

Citovat

JANCUSKOVA, T; R PLACHY; Jiří ŠTIKA; L ZEMANKOVA; DW HARDEKOPF; T LIEHR; N KOSYAKOVA; R CMEJLA; L ZEJSKOVA; T KOZAK; P ZAK; A ZAVRELOVA; P HAVLIKOVA; M KARAS; A JUNGE; C RAMEL a S PEKOVA. A method to identify new molecular markers for assessing minimal residual disease in acute leukemia patients. Leukemia Research. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD, 2013, roč. 37, č. 10, s. 1363-1373. ISSN 0145-2126. Dostupné z: https://doi.org/10.1016/j.leukres.2013.06.009.

@article{1429320,
   author = {Jancuskova, T and Plachy, R and Štika, Jiří and Zemankova, L and Hardekopf, DW and Liehr, T and Kosyakova, N and Cmejla, R and Zejskova, L and Kozak, T and Zak, P and Zavrelova, A and Havlikova, P and Karas, M and Junge, A and Ramel, C and Pekova, S},
   article_location = {OXFORD},
   article_number = {10},
   doi = {https://doi.org/10.1016/j.leukres.2013.06.009},
   keywords = {Acute leukemia; Minimal residual disease; Cytogenetics; Chromosome microdissection; Next-generation sequencing; Personalized medicine},
   language = {eng},
   issn = {0145-2126},
   journal = {Leukemia Research},
   title = {A method to identify new molecular markers for assessing minimal residual disease in acute leukemia patients},
   volume = {37},
   year = {2013}
}

TY  - JOUR
ID  - 1429320
AU  - Jancuskova, T - Plachy, R - Štika, Jiří - Zemankova, L - Hardekopf, DW - Liehr, T - Kosyakova, N - Cmejla, R - Zejskova, L - Kozak, T - Zak, P - Zavrelova, A - Havlikova, P - Karas, M - Junge, A - Ramel, C - Pekova, S
PY  - 2013
TI  - A method to identify new molecular markers for assessing minimal residual disease in acute leukemia patients
JF  - Leukemia Research
VL  - 37
IS  - 10
SP  - 1363-1373
EP  - 1363-1373
PB  - PERGAMON-ELSEVIER SCIENCE LTD
SN  - 01452126
KW  - Acute leukemia
KW  - Minimal residual disease
KW  - Cytogenetics
KW  - Chromosome microdissection
KW  - Next-generation sequencing
KW  - Personalized medicine
N2  - Acute leukemias (AL) comprise a heterogeneous group of hematologic malignancies, and individual patient responses to treatment can be difficult to predict. Monitoring of minimal residual disease (MRD) is thus very important and holds great potential for improving treatment strategies. Common MRD targets include recurrent cytogenetic abnormalities and mutations in important hematological genes; unfortunately well-characterized targets are lacking in many AL patients. Here we demonstrate a technical approach for the identification and mapping of novel clone-specific chromosomal abnormalities down to the nucleotide level. We used molecular cytogenetics, chromosome microdissection, amplification of the microdissected material, and next-generation sequencing to develop PCR-based MRD assays based on unique breakpoint sequences. (C) 2013 Elsevier Ltd. All rights reserved.
ER  -

JANCUSKOVA, T; R PLACHY; Jiří ŠTIKA; L ZEMANKOVA; DW HARDEKOPF; T LIEHR; N KOSYAKOVA; R CMEJLA; L ZEJSKOVA; T KOZAK; P ZAK; A ZAVRELOVA; P HAVLIKOVA; M KARAS; A JUNGE; C RAMEL a S PEKOVA. A method to identify new molecular markers for assessing minimal residual disease in acute leukemia patients. \textit{Leukemia Research}. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD, 2013, roč.~37, č.~10, s.~1363-1373. ISSN~0145-2126. Dostupné z: https://doi.org/10.1016/j.leukres.2013.06.009.

Přehled o publikaci